Mesa Cost Of Revenue vs Capex To Revenue Analysis

MLAB Stock

USD 133.31 2.60 1.91%

Mesa Laboratories financial indicator trend analysis is infinitely more than just investigating Mesa Laboratories recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mesa Laboratories is a good investment. Please check the relationship between Mesa Laboratories Cost Of Revenue and its Capex To Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mesa Laboratories Cost Of Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Mesa Laboratories' Cost Of Revenue and Capex To Revenue is -0.45. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Mesa Laboratories, assuming nothing else is changed. The correlation between historical values of Mesa Laboratories' Cost Of Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Mesa Laboratories are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Cost Of Revenue i.e., Mesa Laboratories' Cost Of Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.45

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Mesa Laboratories income statement and represents the costs associated with goods and services Mesa Laboratories provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Mesa Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mesa Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.At present, Mesa Laboratories' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 26.84, whereas Tax Provision is projected to grow to (20.3 M).

	2021	2022	2023	2024 (projected)
Gross Profit	109.1M	133.7M	110.8M	116.3M
Total Revenue	184.3M	219.1M	216.2M	227.0M

Gross Profit Total Revenue

Mesa Laboratories fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Total	Other Current Assets	Short Long Term Debt Total	Accounts Payable	Short Term Debt	Intangible Assets	Common Stock Total Equity
Total Assets		0.9	0.91	0.9	0.71	0.48	-0.14	0.56	0.97	0.62	0.62	0.56	0.91	0.94	0.77	0.47	0.93	0.8	0.81	0.92	0.74	0.91	0.92	-0.42	0.75	0.91
Other Current Liab	0.9		0.98	0.72	0.85	0.59	-0.25	0.4	0.89	0.57	0.48	0.4	0.91	0.86	0.82	0.37	0.9	0.87	0.68	0.89	0.57	0.89	0.95	-0.5	0.73	0.86
Total Current Liabilities	0.91	0.98		0.69	0.89	0.7	-0.37	0.32	0.92	0.55	0.46	0.32	0.97	0.88	0.9	0.38	0.96	0.94	0.65	0.94	0.56	0.95	0.98	-0.48	0.73	0.92
Total Stockholder Equity	0.9	0.72	0.69		0.41	0.13	0.26	0.69	0.84	0.49	0.7	0.69	0.67	0.86	0.48	0.48	0.67	0.51	0.81	0.67	0.83	0.64	0.72	-0.34	0.6	0.68
Property Plant And Equipment Net	0.71	0.85	0.89	0.41		0.73	-0.54	0.17	0.73	0.57	0.19	0.17	0.86	0.7	0.86	0.15	0.85	0.95	0.49	0.84	0.29	0.86	0.83	-0.48	0.59	0.81
Net Debt	0.48	0.59	0.7	0.13	0.73		-0.61	-0.38	0.64	0.17	0.09	-0.38	0.77	0.48	0.85	0.31	0.73	0.83	-0.01	0.73	0.27	0.73	0.71	-0.24	0.49	0.62
Retained Earnings	-0.14	-0.25	-0.37	0.26	-0.54	-0.61		0.15	-0.15	-0.24	0.22	0.15	-0.42	-0.21	-0.53	0.17	-0.46	-0.53	-0.07	-0.47	0.4	-0.51	-0.33	0.07	-0.19	-0.52
Cash	0.56	0.4	0.32	0.69	0.17	-0.38	0.15		0.35	0.61	0.49	1.0	0.25	0.53	0.05	0.1	0.35	0.11	0.92	0.36	0.29	0.36	0.31	-0.26	0.4	0.46
Non Current Assets Total	0.97	0.89	0.92	0.84	0.73	0.64	-0.15	0.35		0.5	0.59	0.35	0.94	0.91	0.84	0.53	0.93	0.85	0.64	0.93	0.78	0.91	0.95	-0.4	0.74	0.88
Non Currrent Assets Other	0.62	0.57	0.55	0.49	0.57	0.17	-0.24	0.61	0.5		-0.04	0.61	0.55	0.56	0.54	-0.29	0.62	0.49	0.74	0.62	0.36	0.63	0.47	-0.41	0.29	0.62
Other Assets	0.62	0.48	0.46	0.7	0.19	0.09	0.22	0.49	0.59	-0.04		0.49	0.42	0.56	0.17	0.91	0.46	0.28	0.54	0.46	0.54	0.44	0.56	-0.18	0.8	0.45
Cash And Short Term Investments	0.56	0.4	0.32	0.69	0.17	-0.38	0.15	1.0	0.35	0.61	0.49		0.25	0.53	0.05	0.1	0.35	0.11	0.92	0.36	0.29	0.36	0.31	-0.26	0.4	0.46
Net Receivables	0.91	0.91	0.97	0.67	0.86	0.77	-0.42	0.25	0.94	0.55	0.42	0.25		0.88	0.95	0.38	0.97	0.96	0.59	0.97	0.61	0.96	0.97	-0.37	0.69	0.94
Common Stock Shares Outstanding	0.94	0.86	0.88	0.86	0.7	0.48	-0.21	0.53	0.91	0.56	0.56	0.53	0.88		0.76	0.4	0.89	0.79	0.76	0.88	0.64	0.87	0.89	-0.41	0.68	0.9
Inventory	0.77	0.82	0.9	0.48	0.86	0.85	-0.53	0.05	0.84	0.54	0.17	0.05	0.95	0.76		0.19	0.91	0.95	0.42	0.9	0.51	0.9	0.89	-0.34	0.51	0.86
Other Stockholder Equity	0.47	0.37	0.38	0.48	0.15	0.31	0.17	0.1	0.53	-0.29	0.91	0.1	0.38	0.4	0.19		0.39	0.29	0.19	0.39	0.48	0.36	0.51	-0.07	0.77	0.31
Total Liab	0.93	0.9	0.96	0.67	0.85	0.73	-0.46	0.35	0.93	0.62	0.46	0.35	0.97	0.89	0.91	0.39		0.92	0.67	1.0	0.55	1.0	0.95	-0.43	0.77	0.97
Property Plant And Equipment Gross	0.8	0.87	0.94	0.51	0.95	0.83	-0.53	0.11	0.85	0.49	0.28	0.11	0.96	0.79	0.95	0.29	0.92		0.47	0.91	0.44	0.93	0.92	-0.42	0.62	0.88
Total Current Assets	0.81	0.68	0.65	0.81	0.49	-0.01	-0.07	0.92	0.64	0.74	0.54	0.92	0.59	0.76	0.42	0.19	0.67	0.47		0.67	0.45	0.68	0.63	-0.36	0.59	0.75
Non Current Liabilities Total	0.92	0.89	0.94	0.67	0.84	0.73	-0.47	0.36	0.93	0.62	0.46	0.36	0.97	0.88	0.9	0.39	1.0	0.91	0.67		0.55	1.0	0.94	-0.41	0.77	0.97
Other Current Assets	0.74	0.57	0.56	0.83	0.29	0.27	0.4	0.29	0.78	0.36	0.54	0.29	0.61	0.64	0.51	0.48	0.55	0.44	0.45	0.55		0.5	0.62	-0.27	0.45	0.46
Short Long Term Debt Total	0.91	0.89	0.95	0.64	0.86	0.73	-0.51	0.36	0.91	0.63	0.44	0.36	0.96	0.87	0.9	0.36	1.0	0.93	0.68	1.0	0.5		0.94	-0.43	0.77	0.97
Accounts Payable	0.92	0.95	0.98	0.72	0.83	0.71	-0.33	0.31	0.95	0.47	0.56	0.31	0.97	0.89	0.89	0.51	0.95	0.92	0.63	0.94	0.62	0.94		-0.41	0.79	0.91
Short Term Debt	-0.42	-0.5	-0.48	-0.34	-0.48	-0.24	0.07	-0.26	-0.4	-0.41	-0.18	-0.26	-0.37	-0.41	-0.34	-0.07	-0.43	-0.42	-0.36	-0.41	-0.27	-0.43	-0.41		-0.34	-0.37
Intangible Assets	0.75	0.73	0.73	0.6	0.59	0.49	-0.19	0.4	0.74	0.29	0.8	0.4	0.69	0.68	0.51	0.77	0.77	0.62	0.59	0.77	0.45	0.77	0.79	-0.34		0.7
Common Stock Total Equity	0.91	0.86	0.92	0.68	0.81	0.62	-0.52	0.46	0.88	0.62	0.45	0.46	0.94	0.9	0.86	0.31	0.97	0.88	0.75	0.97	0.46	0.97	0.91	-0.37	0.7

Click cells to compare fundamentals

Mesa Laboratories Account Relationship Matchups

Mesa Laboratories fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	420.2M	600.2M	707.4M	661.8M	446.8M	469.1M
Other Current Liab	14.7M	18.3M	22.8M	20.0M	19.8M	20.8M
Total Current Liabilities	26.0M	32.6M	48.1M	43.4M	44.3M	46.5M
Total Stockholder Equity	220.0M	406.2M	393.8M	393.5M	145.4M	74.1M
Property Plant And Equipment Net	22.1M	22.0M	28.6M	28.1M	41.4M	43.5M
Net Debt	60.0M	(117.2M)	171.8M	137.4M	203.1M	213.2M
Retained Earnings	71.9M	72.5M	76.7M	74.2M	(183.5M)	(174.3M)
Cash	81.4M	263.9M	49.3M	32.9M	28.2M	17.3M
Non Current Assets Total	297.4M	297.1M	583.1M	542.9M	337.4M	354.3M
Non Currrent Assets Other	275.3M	275.1M	11.8M	209.0M	194.9M	204.7M
Other Assets	11.5M	275.1M	554.4M	2.8M	1.0	0.95
Cash And Short Term Investments	81.4M	263.9M	49.3M	32.9M	28.2M	17.5M
Net Receivables	21.1M	23.8M	41.2M	42.6M	39.1M	41.0M
Common Stock Shares Outstanding	4.4M	5.1M	5.3M	5.4M	5.4M	4.3M
Liabilities And Stockholders Equity	420.2M	600.2M	707.4M	661.8M	446.8M	469.1M
Inventory	14.2M	11.2M	24.6M	34.6M	32.7M	34.3M
Other Stockholder Equity	60K	16.1M	323.1M	(12.8M)	(1.0)	(0.95)
Total Liab	200.2M	193.9M	313.6M	268.4M	301.4M	316.5M
Property Plant And Equipment Gross	22.1M	22.0M	46.3M	47.9M	54.3M	57.0M
Total Current Assets	122.8M	303.0M	124.3M	119.0M	109.4M	114.8M
Accumulated Other Comprehensive Income	(9.9M)	16.1M	3.7M	(12.8M)	(14.8M)	(14.0M)
Non Current Liabilities Total	174.2M	162.7M	265.5M	225.0M	257.1M	269.9M
Other Current Assets	41.4M	39.1M	75.0M	86.1M	9.4M	13.4M
Short Long Term Debt Total	141.4M	146.7M	221.1M	186.1M	231.3M	242.9M
Accounts Payable	3.4M	4.5M	7.9M	6.1M	6.0M	6.3M
Short Term Debt	1.1M	1.0M	2.8M	2.9M	3.0M	2.3M
Intangible Assets	119.9M	111.7M	250.1M	18.2M	113.8M	119.4M
Common Stock Total Equity	39.8M	158.0M	317.7M	332.1M	381.9M	401.0M
Common Stock	158.0M	317.7M	313.5M	332.1M	343.6M	360.8M
Property Plant Equipment	22.1M	22.0M	28.6M	28.1M	32.4M	34.0M
Good Will	141.5M	160.8M	291.2M	286.4M	180.1M	189.1M
Current Deferred Revenue	6.8M	8.8M	14.6M	14.4M	15.5M	16.3M
Long Term Debt	140.3M	145.7M	218.4M	183.3M	221.7M	232.8M
Net Tangible Assets	(41.4M)	294.5M	393.8M	107.0M	123.1M	101.8M
Retained Earnings Total Equity	73.3M	71.9M	72.5M	74.2M	85.3M	68.3M
Other Liab	32.6M	193.9M	39.7M	36.0M	41.4M	32.9M
Long Term Debt Total	20.6M	140.3M	145.7M	183.3M	210.8M	221.3M
Non Current Liabilities Other	1.4M	715K	7.9M	7.7M	15.6M	16.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
F	Ford Motor
CRM	Salesforce

When determining whether Mesa Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesa Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesa Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesa Laboratories Stock:

How To Invest In Mesa

Details

Is Mesa Stock a good investment?

Details

What is Mesa Laboratories' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. If investors know Mesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesa Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

3.875

Dividend Share

0.64

Earnings Share

(46.49)

Revenue Per Share

41.488

Quarterly Revenue Growth

0.149

The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mesa Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesa Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesa Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mesa Cost Of Revenue vs Capex To Revenue Analysis

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Capex To Revenue

Mesa Laboratories fundamental ratios Correlations

Mesa Laboratories Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mesa Laboratories fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 1.0	Total Liab
Short Long Term Debt Total	+ 1.0	Total Liab
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total
Total Current Liabilities	+ 0.98	Other Current Liab
Accounts Payable	+ 0.98	Total Current Liabilities

Retained Earnings	- 0.61	Net Debt
Retained Earnings	- 0.54	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.53	Retained Earnings
Inventory	- 0.53	Retained Earnings
Common Stock Total Equity	- 0.52	Retained Earnings
Short Long Term Debt Total	- 0.51	Retained Earnings